Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Valenta Pharm JSC clinical trials
The registry lists 40 studies whose lead sponsor is Valenta Pharm JSC. 18 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 15, 2026.
Keep track of what changes. Save the Valenta Pharm JSC studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Valenta Pharm JSC.
- Valenta Pharm JSC40 studiesSame company
Something wrong?
Focus areas
Conditions Valenta Pharm JSC leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 40 of 40.
- Food-Effect, Single and Multiple Dose Pharmacokinetics, Safety and Tolerability Study of 4-MUST, 128 mg, Tablets in Healthy VolunteersRecruitingNCT07594977Phase 1
- Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.RecruitingNCT07645534Phase 1
- Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary DyskinesiaRecruitingNCT07595003Phase 3
- Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.RecruitingNCT07421011Phase 1
- Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.RecruitingNCT07420985Phase 2
- Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary DyskinesiaRecruitingNCT06842966Phase 2
- Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy VolunteersRecruitingNCT06859281Phase 1
- Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With Drug Septolete Total, LozengesRecruitingNCT06843018Phase 2
- Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy VolunteersRecruitingNCT06857890Phase 1
- Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment DisordersRecruitingNCT06843044Phase 4
- Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy VolunteersRecruitingNCT06859333Phase 1
- Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional VertigoRecruitingNCT06321341Phase 4
- Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy VolunteersRecruitingNCT06098742Not applicable
- Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral InfectionsRecruitingNCT06379542Phase 3
- Food Effect on the Bioavailability of 4-MUST, Tablets, 128 mgRecruitingNCT06342804Phase 1
- Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral InfectionsRecruitingNCT06315400Phase 4
- Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy VolunteersNot yet recruitingNCT06096571Not applicable
- Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy VolunteersRecruitingNCT06315387Phase 1
- Pharmacokinetics and Bioequivalence of Doxylamine+Pyridoxine and Diclectin Under Fed Conditions in Healthy VolunteersCompletedNCT06342778Phase 1
- Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 800 mg Chewable Tablets in Healthy VolunteersCompletedNCT06552624Not applicable
- Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted VolunteersCompletedNCT05558462Not applicable
- Efficacy and Safety of Dioxidin Versus Miramistin in Superficial PyodermaCompletedNCT05561816Phase 3
- A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory InfectionsCompletedNCT05544916Phase 3
- Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External Use, 5 mg/ml in Healthy VolunteersCompletedNCT05505097Phase 1
- Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy VolunteersCompletedNCT05412173Not applicable
- Study of the Effect of Food Intake on the Bioavailability of XC8 10 mg Film-coated TabletsCompletedNCT05294250Phase 1
- A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment DisordersCompletedNCT05586789Phase 3
- A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory InfectionsCompletedNCT05030324Phase 2
- Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral InfectionCompletedNCT05273619Phase 3
- Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral InfectionsCompletedNCT05269290Phase 3
- Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg TabletsCompletedNCT05295121Phase 1
- Pharmacokinetics and Bioequivalence of Doxylamine + Pyridoxine, Film-coated, Enteric-soluble Tablets, and Diclectin, Delayed Release Tablets, in Healthy VolunteersCompletedNCT05498233Not applicable
- Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19CompletedNCT05216497Phase 3
- Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by VertigoCompletedNCT05430217Phase 3
- Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral InfectionCompletedNCT05269329Phase 2
- Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.CompletedNCT03206346Phase 3
- Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.CompletedNCT03191097Phase 3
- Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral InfectionsCompletedNCT03189537Phase 3
- Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in AdultsCompletedNCT03154515Phase 4
- Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.CompletedNCT02644018Phase 3